The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review

Giuseppe Di Lorenzo, S. De Placido, Martina Pagliuca, Giuseppe Lucarelli, S. Rossetti, Davide Bosso, Livio Puglia, Piero Pignataro, Ilaria Ascione, Michele Caraglia, Daniela Terracciano, Gaetano Facchini, C. Buonerba, Guru Sonpavde

Research output: Contribution to journalReview article

Abstract

Introduction: While the majority of the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitors currently used for the therapy of metastatic renal cell carcinoma (mRCC) are small molecule agents inhibiting multiple targets, monoclonal antibodies are inhibitors of specific targets, which may decrease off-target effects while preserving on-target activity. A few monoclonal antibodies have already been approved for mRCC (bevacizumab, nivolumab), while many others may play an important role in the therapeutic scenario of mRCC. Areas covered: This review describes emerging monoclonal antibodies for treating RCC. Currently, bevacizumab, a VEGF monoclonal antibody, is approved in combination with interferon for the therapy of metastatic RCC, while nivolumab, a Programmed Death (PD)-1 inhibitor, is approved following prior VEGF inhibitor treatment. Other PD-1 and PD-ligand (L)-1 inhibitors are undergoing clinical development. Expert opinion: Combinations of inhibitors of the PD1/PD-L1 axis with VEGF inhibitors or cytotoxic T-lymphocyte antigen (CTLA)-4 inhibitors have shown promising efficacy in mRCC. The development of biomarkers predictive for benefit and rational tolerable combinations are both important pillars of research to improve outcomes in RCC.

Original languageEnglish
Pages (from-to)1387-1401
Number of pages15
JournalExpert Opinion on Biological Therapy
Volume16
Issue number11
DOIs
Publication statusPublished - Nov 1 2016

Fingerprint

Renal Cell Carcinoma
Vascular Endothelial Growth Factor A
Monoclonal Antibodies
Cells
CTLA-4 Antigen
Expert Testimony
Biomarkers
Sirolimus
Therapeutics
Interferons
Ligands
Molecules
Research
nivolumab
Bevacizumab

Keywords

  • bevacizumab
  • Kidney neoplasm
  • monoclonal antibodies
  • nivolumab
  • targeted therapy

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma : a systematic review. / Di Lorenzo, Giuseppe; De Placido, S.; Pagliuca, Martina; Lucarelli, Giuseppe; Rossetti, S.; Bosso, Davide; Puglia, Livio; Pignataro, Piero; Ascione, Ilaria; Caraglia, Michele; Terracciano, Daniela; Facchini, Gaetano; Buonerba, C.; Sonpavde, Guru.

In: Expert Opinion on Biological Therapy, Vol. 16, No. 11, 01.11.2016, p. 1387-1401.

Research output: Contribution to journalReview article

Di Lorenzo, G, De Placido, S, Pagliuca, M, Lucarelli, G, Rossetti, S, Bosso, D, Puglia, L, Pignataro, P, Ascione, I, Caraglia, M, Terracciano, D, Facchini, G, Buonerba, C & Sonpavde, G 2016, 'The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review', Expert Opinion on Biological Therapy, vol. 16, no. 11, pp. 1387-1401. https://doi.org/10.1080/14712598.2016.1216964
Di Lorenzo, Giuseppe ; De Placido, S. ; Pagliuca, Martina ; Lucarelli, Giuseppe ; Rossetti, S. ; Bosso, Davide ; Puglia, Livio ; Pignataro, Piero ; Ascione, Ilaria ; Caraglia, Michele ; Terracciano, Daniela ; Facchini, Gaetano ; Buonerba, C. ; Sonpavde, Guru. / The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma : a systematic review. In: Expert Opinion on Biological Therapy. 2016 ; Vol. 16, No. 11. pp. 1387-1401.
@article{ae937a6bbeab48c3aff62de8c1d1b5d6,
title = "The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review",
abstract = "Introduction: While the majority of the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitors currently used for the therapy of metastatic renal cell carcinoma (mRCC) are small molecule agents inhibiting multiple targets, monoclonal antibodies are inhibitors of specific targets, which may decrease off-target effects while preserving on-target activity. A few monoclonal antibodies have already been approved for mRCC (bevacizumab, nivolumab), while many others may play an important role in the therapeutic scenario of mRCC. Areas covered: This review describes emerging monoclonal antibodies for treating RCC. Currently, bevacizumab, a VEGF monoclonal antibody, is approved in combination with interferon for the therapy of metastatic RCC, while nivolumab, a Programmed Death (PD)-1 inhibitor, is approved following prior VEGF inhibitor treatment. Other PD-1 and PD-ligand (L)-1 inhibitors are undergoing clinical development. Expert opinion: Combinations of inhibitors of the PD1/PD-L1 axis with VEGF inhibitors or cytotoxic T-lymphocyte antigen (CTLA)-4 inhibitors have shown promising efficacy in mRCC. The development of biomarkers predictive for benefit and rational tolerable combinations are both important pillars of research to improve outcomes in RCC.",
keywords = "bevacizumab, Kidney neoplasm, monoclonal antibodies, nivolumab, targeted therapy",
author = "{Di Lorenzo}, Giuseppe and {De Placido}, S. and Martina Pagliuca and Giuseppe Lucarelli and S. Rossetti and Davide Bosso and Livio Puglia and Piero Pignataro and Ilaria Ascione and Michele Caraglia and Daniela Terracciano and Gaetano Facchini and C. Buonerba and Guru Sonpavde",
year = "2016",
month = "11",
day = "1",
doi = "10.1080/14712598.2016.1216964",
language = "English",
volume = "16",
pages = "1387--1401",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",
number = "11",

}

TY - JOUR

T1 - The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma

T2 - a systematic review

AU - Di Lorenzo, Giuseppe

AU - De Placido, S.

AU - Pagliuca, Martina

AU - Lucarelli, Giuseppe

AU - Rossetti, S.

AU - Bosso, Davide

AU - Puglia, Livio

AU - Pignataro, Piero

AU - Ascione, Ilaria

AU - Caraglia, Michele

AU - Terracciano, Daniela

AU - Facchini, Gaetano

AU - Buonerba, C.

AU - Sonpavde, Guru

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Introduction: While the majority of the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitors currently used for the therapy of metastatic renal cell carcinoma (mRCC) are small molecule agents inhibiting multiple targets, monoclonal antibodies are inhibitors of specific targets, which may decrease off-target effects while preserving on-target activity. A few monoclonal antibodies have already been approved for mRCC (bevacizumab, nivolumab), while many others may play an important role in the therapeutic scenario of mRCC. Areas covered: This review describes emerging monoclonal antibodies for treating RCC. Currently, bevacizumab, a VEGF monoclonal antibody, is approved in combination with interferon for the therapy of metastatic RCC, while nivolumab, a Programmed Death (PD)-1 inhibitor, is approved following prior VEGF inhibitor treatment. Other PD-1 and PD-ligand (L)-1 inhibitors are undergoing clinical development. Expert opinion: Combinations of inhibitors of the PD1/PD-L1 axis with VEGF inhibitors or cytotoxic T-lymphocyte antigen (CTLA)-4 inhibitors have shown promising efficacy in mRCC. The development of biomarkers predictive for benefit and rational tolerable combinations are both important pillars of research to improve outcomes in RCC.

AB - Introduction: While the majority of the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitors currently used for the therapy of metastatic renal cell carcinoma (mRCC) are small molecule agents inhibiting multiple targets, monoclonal antibodies are inhibitors of specific targets, which may decrease off-target effects while preserving on-target activity. A few monoclonal antibodies have already been approved for mRCC (bevacizumab, nivolumab), while many others may play an important role in the therapeutic scenario of mRCC. Areas covered: This review describes emerging monoclonal antibodies for treating RCC. Currently, bevacizumab, a VEGF monoclonal antibody, is approved in combination with interferon for the therapy of metastatic RCC, while nivolumab, a Programmed Death (PD)-1 inhibitor, is approved following prior VEGF inhibitor treatment. Other PD-1 and PD-ligand (L)-1 inhibitors are undergoing clinical development. Expert opinion: Combinations of inhibitors of the PD1/PD-L1 axis with VEGF inhibitors or cytotoxic T-lymphocyte antigen (CTLA)-4 inhibitors have shown promising efficacy in mRCC. The development of biomarkers predictive for benefit and rational tolerable combinations are both important pillars of research to improve outcomes in RCC.

KW - bevacizumab

KW - Kidney neoplasm

KW - monoclonal antibodies

KW - nivolumab

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84989298043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989298043&partnerID=8YFLogxK

U2 - 10.1080/14712598.2016.1216964

DO - 10.1080/14712598.2016.1216964

M3 - Review article

VL - 16

SP - 1387

EP - 1401

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 11

ER -